The specific thromboxane receptor antagonist S18886: Pharmacokinetic and pharmacodynamic studies

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 7, 2005, Pages 1437-1445

  Gaussem, Pascale ^a   Reny, J L ^a   Thalamas, C ^b   Chatelain, N ^c   Kroumova, M ^d   Jude, B ^c   Boneu, B ^e   Fiessinger, J N ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b CHU PURPAN   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d University of Lille   (France)

^e CHU RANGUEIL   (France)

Author keywords

Antiplatelet drugs; Pharmacodynamics; Pharmacokinetics; Platelet aggregation; Thromboxane receptor antagonist; TP

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENZODIAZEPINE; DACRON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; S18886; THROMBOXANE RECEPTOR BLOCKING AGENT; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 ((6 AMINO (4 CHLOROBENZENESULFONYL) 2 METHYL 5,6,7,8 TETRAHYDRONAPHT) 1 YL)PROPIONIC ACID; 3-((6-AMINO-(4-CHLOROBENZENESULFONYL)-2-METHYL-5,6,7,8-TETRAHYDRONAPHT)-1-YL)PROPIONIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; NAPHTHALENE DERIVATIVE; PROPIONIC ACID DERIVATIVE; THROMBOXANE RECEPTOR;

ADULT; ARTERY DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; MALE; MULTICENTER STUDY; PARALYTIC ILEUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE AGGREGATION; AGED; AREA UNDER THE CURVE; DRUG ANTAGONISM; DRUG EFFECT; KINETICS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; AGED; ARACHIDONIC ACID; AREA UNDER CURVE; COLLAGEN; FEMALE; HUMANS; KINETICS; MALE; MIDDLE AGED; NAPHTHALENES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROPIONIC ACIDS; RECEPTORS, THROMBOXANE; TIME FACTORS;

EID: 25144437017     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01468.x     Document Type: Article

References (37)

1. Narumiya S. Prostanoid receptors. Structure, function, and distribution. Ann N Y Acad Sci 1994; 744: 126-38.
2. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-90.
3. Audoly LP, Rocca B, Fahre JE, Koller BH, Thomas D, Loeb AL, Coffman TM, FitzGerald GA. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000; 101: 2833-40.
4. Bhagwat SS, Hamann PR, Still WC, Bunting S, Fitzpatrick FA. Synthesis and structure of the platelet aggregation factor thromboxane A2. Nature 1985; 315: 511-3.
5. Vezza R, Mezzasoma AM, Venditti G, Gresele P. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thromb Haemost 2002; 87: 114-21.
6. Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000; 96: 3823-6.
7. Pratico D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001; 12: 243-7.
8. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
9. Hankey GJ, Eikelboom JW. Antiplatelet drugs. Med J Aust 2003; 178: 568-74.
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
11. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108: 7-13.
12. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17: 2309-15.
13. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
14. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
15. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998; 79: 691-705.
16. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-3.
17. Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 1987; 80: 1435-45.
18. Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 1990; 81: 169-78; discussion 179-80.
19. Simonet S, Descombes JJ, Vallez MO, Dubuffet T, Lavielle G, Verbeuren TJ. S18886, a new thromboxane (TP)-receptor antagonist, is the active isomer of S18204 in all species, except in the guinea-pig. Adv Exp Med Biol 1997; 433: 173-6.
20. Fiessinger JN. S18886, a new specific TP-receptor antagonist, is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease. Eur Heart J 2004; 25: P573.
21. Osende JI, Shimbo D, Fuster V, Dubar M, Badimon JJ. Antithrombotic effects of S18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004; 2: 492-8.
22. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41: 1198-204.
23. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-41.
24. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-8.
25. Ogren M, Hedblad B, Isacsson SO, Janzon L, Jungquist G, Lindell SE. Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet 1993; 342: 1138-41.
26. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, Wolfson SK. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993; 88: 837-45.
27. Gresele P, Catalano M, Giammarresi C, Volpato R, Termini R, Ciabattoni G, Nenci GG, Davi G. Platelet activation markers in patients with peripheral arterial disease - a prospective comparison of different platelet function tests. Thromb Haemost 1997; 78: 1434-7.
28. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-30.
29. Schumacher WA, Heran CL, Goldenberg HJ, Harris DN, Ogletree ML. Magnitude of thromboxane receptor antagonism necessary for antithrombotic activity in monkeys. Am J Physiol 1989; 256: H726-34.
30. Yamada N, Miyamoto M, Isogaya M, Suzuki M, Ikezawa S, Ohno M, Otake A, Umemura K. TRA-418, a novel compound having both thromboxane A2 receptor antagonistic and prostaglandin 12 receptor agonistic activities: its antiplatelet effects in human and animal platelets. J Thromb Haemost 2003; 1: 1813-9.
31. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998; 97: 5-9.
32. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-32.
33. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996; 76: 939-43.
34. Claeys MJ, Van Der Planken MG, Michiels JJ, Vertessen F, Dilling D, Bosnians JM, Vrints CJ. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. Blood Coagul Fibrinolysis 2002; 13: 283-8.
35. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-8.
36. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
37. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/ IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999; 100: 437-44.